Global Plasma Fractionation Market is expected to reach USD 41.95 Billion by 2024 from USD 24.75 Billion in 2016 at CAGR of 6.82% (Detailed analysis of the market CAGR is provided in the report).
Plasma Fractionation is basically process where various components of plasma are separated through blood fractionation and then Fresh Frozen Plasma (FFP) can be used for replacement of clotting factors. Plasma Fractionation is useful in prevention and treatment of life threatening diseases caused by trauma, immunologic disorders, and infections.
Global Plasma Fractionation Market is segmented by product, application, end user, and geography. Product segment is sub segmented as immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors and other plasma products. Application segment is divided as neurology, immunology, hematology, critical care and others. End user segment is classified as hospitals & clinics, clinical research laboratories and academic institutes. Hospital and clinic end user segment is expected to lead the market growth during the forecast period. This growth is attributed to increasing number of hospitals & clinics across the globe and increasing adoption of plasma products in the treatment of various diseases. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa and Latin America.
Increasing geriatric population across the globe and rising prevalence of respiratory diseases are trending the overall Global Plasma Fractionation Market. However, high cost and limited reimbursement will restrain the market growth. North America is expected to dominate the Plasma Fractionation Market in forecast period followed by Europe and APAC. Technologically advanced research and increased use of immunoglobulins in neurological diseases and prophylaxis treatments for diagnosed patients in this region will fuel the Plasma Fractionation Market in North America region.
This Information Submitted By Market Research Company (Maximize Market Research PVT.LTD)